The Plasma Proteins Therapeutic Association recently released a statement about the effect of the COVID-19 pandemic on source plasma donations and the critical need for plasma donations.
There is an urgent need for plasma donations. Reports vary, but plasma collectors experienced significant declines in collections due, in part, to the impacts of social distancing measures and other mobility restrictions caused by the COVID-19 pandemic.1,2 Considering the complex manufacturing of plasma-derived therapies can take 7-12 months, any decline in plasma donations could impact patients’ ability to access their lifesaving therapies.3,4. This sharp decline in plasma collections currently being experienced could cause more significant challenges in the months to come.
The COVID-19 pandemic has shed a light on certain barriers with the potential to impact patient access to plasma-derived therapies. PPTA continues to appeal to authorities in the U.S. to address the barriers that impede the private sector’s ability to collect plasma in certain states, and in Europe, we repeat our call for the coexistence of the private sector with the public sector to collect more plasma. These common-sense updates can be accomplished with no impact on the safety of donors or on the finished products. The same urgency for patients suffering from COVID-19 exists for those with chronic and rare diseases whose lives depend on plasma-derived therapies.
You can read the full statement here>>
Get the latest information regarding plasma in through our news & updates. Featuring: Scientific discoveries, plasma supply, industry related coverage, policy and legislation, and more!